That was only for the safety data, The rest of the Data had been...

That was only for the safety data,
The rest of the Data had been released and shown on the Ann.

"The data from this BIT225-009 trial is consistent with the targeting and eradication of HIV-1 virus from these key reservoir cells in the BIT225-treated patients.

In addition to the beneficial immunological effects, there was a significant reduction in the level of the macrophage activation marker sCD163 in the BIT225-treated population by the end of the treatment period. Higher levels of sCD163 are linked with worse clinical outcomes in patients. This reduction of sCD163 by BIT225 may provide additional clinical benefit in these patients.

2 The headline results indicate that BIT225 has had a profound effect on a source of virus that persists in the presence of antiretroviral drugs. Eradication of this virus, produced by long-lived reservoir cells, is central to an eventual HIV cure strategy"

"The trial was designed to assess the safety and antiviral activity of three month’s dosing of BIT225 in combination with antiretroviral drugs in treatment-naïve HIV-positive subjects"

Since the last BIT225-009 Trial results from 2018,
Further long term toxicology studies have been done,
So this time treatment with BIT 225 can be extended to 6 Months.
Previously it could only go to 3 Months.